Scancell Holdings (LSE:SCLP) reported interim results highlighting continued clinical and regulatory progress across its oncology pipeline, led by iSCIB1+, its DNA ImmunoBody cancer immunotherapy. The treatment has shown potentially best-in-class progression-free survival in advanced melanoma when used in combination with checkpoint inhibitors.
During the period, the US Food and Drug Administration cleared an Investigational New Drug application to support a global registrational Phase 3 trial in advanced melanoma. The study is expected to begin in 2026, with potential commercialisation targeted for 2029. Scancell said it is actively evaluating financing and partnering options to fund Phase 3 development while seeking to optimise long-term shareholder value.
Beyond melanoma, the group continues to advance its Moditope-based vaccine Modi-1, which is currently in a Phase 2 trial targeting head and neck and renal cancers, with key data anticipated in the first half of 2026. Scancell has also consolidated its antibody assets within its wholly owned subsidiary GlyMab Therapeutics, where lead candidate SC134 for small cell lung cancer and partnered programmes with Genmab are progressing toward potential milestones in 2026.
On the financial side, the company reported a reduced operating loss of £8.9m for the half year. Cash at period end stood at £8.6m, supplemented by a further £3.0m in R&D tax credits received after the reporting date. Management said current resources provide funding visibility into the second half of 2026, covering several anticipated clinical, regulatory and business development milestones.
Overall, the outlook continues to be constrained by ongoing losses, negative equity and cash burn, although the rate of burn improved during 2025. Technical indicators point to a strong upward trend but appear stretched, increasing the risk of near-term volatility. Management commentary was more supportive, reflecting improved liquidity and meaningful pipeline and regulatory advances, while valuation remains difficult to assess using conventional metrics given the company’s pre-revenue, loss-making status.
More about Scancell Holdings
Scancell Holdings is a clinical-stage biotechnology company developing off-the-shelf active immunotherapies designed to generate durable, tumour-specific immune responses against cancer. Its core platforms, DNA ImmunoBody and Moditope, are being advanced through Phase 2 and planned Phase 3 trials in melanoma and other solid tumours. The group’s subsidiary, GlyMab Therapeutics, is developing high-affinity antibodies targeting tumour-specific glycans, including programmes partnered with Genmab.









